Epcoritamab Clinical Trials
31 recruitingDrug
Phase 226Phase 15Phase 32
Showing 1–20 of 31 trials
Recruiting
Phase 2
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington18 enrolled1 locationNCT07097363
Recruiting
Phase 2
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Genmab1,095 enrolled266 locationsNCT06191744
Recruiting
Phase 2
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Refractory CancerRelapsed CancerLarge Cell Lymphoma, Diffuse
Dipenkumar Modi32 enrolled4 locationsNCT05852717
Recruiting
Phase 2
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez10 enrolled1 locationNCT07451652
Recruiting
Phase 2
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation60 enrolled13 locationsNCT06931652
Recruiting
Phase 2
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
LymphomaFollicular Lymphoma
Beth Israel Deaconess Medical Center35 enrolled3 locationsNCT06510361
Recruiting
Phase 2
Epcoritamab in Previously Treated WM
Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting
Phase 2
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
City of Hope Medical Center33 enrolled7 locationsNCT07218510
Recruiting
Phase 2
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Lymphoma
Memorial Sloan Kettering Cancer Center27 enrolled7 locationsNCT07030699
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 2
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Large B-cell Lymphoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06045247
Recruiting
Phase 2
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RelapseLarge B-cell Lymphoma
University of Miami26 enrolled1 locationNCT06919939
Recruiting
Phase 2
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma
Massachusetts General Hospital30 enrolled2 locationsNCT06811272
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 1Phase 2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 1
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 2
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL+4 more
Zulfa Omer22 enrolled1 locationNCT07108998
Recruiting
Phase 2
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Follicular LymphomaLow Grade Non-Hodgkin's Lymphoma, Adult
Reid Merryman, MD100 enrolled5 locationsNCT05783609